Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab plus rapid corticosteroid taper vs standard corticosteroid taper in polymyalgia rheumatica
jRCT2080224779Phase 3Completed
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of sarilumab in polymyalgia rheumatica (PMR) (2 arms). Primary endpoint: Sustained remission at Week 52. Started Jul 2019; status: completed.
02
Drugs
sarilumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on jRCT2080224779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224779.